Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

RNS - Strategic Alliance Between Xlife Sciences AG, JIPYONG LLC and JIPYONG IP to Accelerate Korean Life Sciences Ventures’ Access to Global Capital Markets

Company: Xlife Sciences AG Date: 2025-06-13 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 

Xlife Sciences AG / Key word(s): Alliance/Partnership  

Strategic Alliance Between Xlife Sciences AG, JIPYONG LLC and JIPYONG IP to Accelerate Korean Life Sciences Ventures’ Access to Global Capital Markets  

  

13.06.2025 / 17:42 CET/CEST  

  

- - -

**Zurich, 13 th of June 2025:** Xlife Sciences AG («Xlife Sciences», SIX: XLS), a Swiss-based incubator and accelerator for life sciences innovation, has entered into a strategic Memorandum of Understanding («MoU») with JIPYONG LLC («JIPYONG»), a premier Korean law firm, and JIPYONG IP («JIPYONG IP»), a leading intellectual property advisory firm. This trilateral collaboration aims to enable high-potential Korean life sciences companies to access international capital markets, including potential listings, while strengthening their global market positioning.

The MoU was formally signed in Seoul by Oliver R. Baumann, Chief Executive Officer of Xlife Sciences AG, Mr. Haeng-Gyu Lee, Managing Partner of JIPYONG LLC, and Mr. Hyuk-Sung Kwon, Managing Partner of JIPYONG IP.

The collaboration encompasses five strategic pillars:

-   Company Identification & Evaluation: Joint scouting and evaluation of promising Korean life sciences ventures across therapeutic areas and development stages.
  

-   Investment Facilitation: Structuring and supporting direct and indirect investments in Korean life sciences companies.
  

-   Capital Market Advisory: Providing regulatory, legal, and strategic guidance for cross-border listings.
  

-   IP Strategy & Protection: Delivering patent portfolio assessments, monetization strategies, and ongoing IP support.
  

-   Market Intelligence & Knowledge Sharing: Promoting a shared ecosystem of insights, trends, and commercialization know-how across regions.

This partnership represents a significant step toward globalizing the Xlife Sciences innovation model and leveraging Korea’s growing life sciences sector. It also positions JIPYONG and JIPYONG IP as key facilitators of global investment and commercialization for Korean biopharma and medtech innovators.

Oliver R. Baumann, CEO of Xlife Sciences AG, stated: « *We are excited to embark on this strategic alliance with JIPYONG and JIPYONG IP. By combining our incubation expertise with their legal and intellectual property strengths, we aim to unlock new growth opportunities for Korean life sciences innovators and expand their access to global capital and commercialization pathways.* »

Mr. Haeng-Gyu Lee, Managing Partner at JIPYONG LLC, commented: « *JIPYONG is committed to supporting Korean life sciences companies in scaling globally. This partnership with Xlife Sciences reflects our belief in the transformative potential of cross-border alliances in achieving sustainable growth and market success* .»

Mr. Hyuk-Sung Kwon, Managing Partner at JIPYONG IP, added: « *Intellectual property is a cornerstone of life sciences value creation. Our collaboration will ensure that Korean innovators have the strategic protection and guidance necessary to succeed on international stages.* »

The MoU serves as a foundation for future joint initiatives and all teams are already working on suitable use cases. Xlife Sciences will therefore not only position itself as a strategic partner for early-stage research projects in Korea, but also enable the access to these markets and partners to its portfolio. Overall, working towards a shared mission to transform high-potential life sciences ventures into global success stories.

**Financial calendar**

|     |     |
| --- | --- |
| Annual Shareholders Meeting 2025 | 24 June 2025 |
| Half-Year Report 2025 | 23 September 2025 |

**Contact**  

Information for investors and journalists: Xlife Sciences AG, Dr. Dennis Fink, [dennis.fink@xlifesciences.ch](mailto:dennis.fink@xlifesciences.ch)

**Xlife Sciences AG,**   

Talacker 35,   

8001 Zurich,   

Switzerland,  

Phone +41 44 385 84 60  

[info@xlifesciences.ch](mailto:info@xlifesciences.ch) , [www.xlifesciences.ch](https://app.schedulr.ch/trace/visit/c5c61a98-9619-4f09-ba5e-effd4a8faa7a) ,   

Commercial Register Zurich CHE-330.279.788   

Stock Exchange: SIX Swiss Exchange

**About Xlife Sciences AG (SIX:XLS)**   

  

Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit [https://www.xlifesciences.ch](https://app.schedulr.ch/trace/visit/ee59de7a-613f-4d08-b1b4-dfd9d83a15db)  

**About JIPYONG LLC**  

  

JIPYONG LLC is a leading Korean law firm recognized for its extensive cross-border experience, particularly in equity capital market transactions, mergers and acquisitions, and regulatory advisory. It supports a wide range of industries, including life sciences, and is committed to facilitating sustainable, international business growth. For more information, visit [https://www.jipyong.com/en/](https://app.schedulr.ch/trace/visit/8f92fadd-d9e0-42fa-8ce9-537468ee98c2)

**About JIPYONG IP**  

  

JIPYONG IP is a specialized intellectual property firm offering expert services in patent strategy, filing, prosecution, and monetization. The firm supports innovation-driven companies in Korea and internationally with tailored IP protection strategies that align with their commercialization goals. For more information, visit [https://www.jipyong.com/en/](https://app.schedulr.ch/trace/visit/b4d1879a-f63e-4c7f-bc84-eec9716e276d)

**Disclaimer**   

  

Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements. 

  

- - -

End of Media Release  

- - -

|     |     |
| --- | --- |
| Language: | English |
| Company: | Xlife Sciences AG |
|     | Talacker 35 |
|     | 8001 Zürich |
|     | Switzerland |
| Phone: | +41 44 385 84 60 |
| E-mail: | info@xlifesciences.ch |
| Internet: | www.xlifesciences.ch |
| ISIN: | CH0461929603 |
| Valor: | A2PK6Z |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 2155114 |

  

|     |     |
| --- | --- |
|     |
| End of News | EQS News Service |

- - -

2155114  13.06.2025 CET/CEST